Immuno-Oncology | Specialty

Monoclonal Antibody Therapy in Myeloma

March 29th 2016

Rationale for Immunotherapy in Multiple Myeloma

March 29th 2016

Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer

March 28th 2016

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Dr. Petrylak on Immunotherapy in Bladder Cancer

March 28th 2016

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses immunotherapy agents for the treatment of patients with bladder cancer.

Immunotherapy a Mainstay in Kidney Cancer, Novel Approaches on Horizon

March 22nd 2016

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Emerging Therapies in HNSCC

March 21st 2016

The Use of Immunotherapy in HNSCC

March 21st 2016

Supportive Care and Long-Term Quality of Life in HNSCC

March 21st 2016

When to Use Cetuximab or Chemotherapy in HNSCC

March 21st 2016

Examining the Use of Cetuximab for HNSCC

March 21st 2016

Chemotherapy Procedures for Advanced HNSCC

March 21st 2016

Roles for Radiotherapy in Head and Neck Cancer

March 21st 2016

Radiation Therapy Approaches to Head and Neck Cancer

March 21st 2016

Surgical Management of HNSCC

March 21st 2016

Head and Neck Cancer: Treatment of Advanced Disease

March 21st 2016

Treatment Approaches in Head and Neck Cancer

March 21st 2016

Multidisciplinary Care in Head and Neck Cancer

March 21st 2016

Diagnosis, Staging, and Prognosis of Head and Neck Cancer

March 21st 2016

Challenges in Implementing Widespread HPV Vaccination

March 21st 2016

HPV Infection in Pathogenesis of Head and Neck Cancers

March 21st 2016